CDKN1B and prostate cancer: Other studies, such as that by Farashi et al. (2018), have demonstrated the possible association of rs2066827 with the risk of developing PCa, resulting from a missense mutation (V109G) in the CDKN1B gene that contributes to prostate cancer tumorigenesis through the deregulation of cell cycle checkpoints [20]; these data corroborate the findings in our study, which demonstrate a positive correlation between the increase in the frequency of this SNP and the increase in the incidence of cases.